Mauna Kea Technologies

Mauna Kea Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Mauna Kea Technologies (ALMKT.PA) as of Nov 5, 2026 is -36.65 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 62.85 % — a change of -158.31% (lower).

FCF Conversion

-36.65 %

YoY

-158.31%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Mauna Kea Technologies is 2025 -36.65 % . FCF Conversion Rate (FCF/EBITDA) of Mauna Kea Technologies was 2024 62.85 % . It decreases by -158.31% lower compared to the previous year.

The Mauna Kea Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
91.96 EUR
Jan 1, 2019
76.30 EUR
Jan 1, 2020
70.92 EUR
Jan 1, 2021
84.57 EUR
Jan 1, 2022
80.27 EUR
Jan 1, 2023
30.45 EUR
Jan 1, 2024
62.85 EUR
Jan 1, 2025
-36.65 EUR
The Mauna Kea Technologies FCF Conversion history
YEARFCF ConversionYoY
-36.65 %-158.31%
62.85 %+106.38%
30.45 %-62.06%
80.27 %-5.09%
84.57 %+19.26%
70.92 %-7.06%
76.30 %-17.02%
91.96 %-10.01%
102.19 %+19.22%
85.71 %-10.38%
95.64 %+0.24%
95.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mauna Kea Technologies Stock analysis

What does Mauna Kea Technologies do? Mauna Kea Technologies is a French company specializing in the development of medical devices. The company was founded in 2000 by Sacha Loiseau, who still leads the company today. The goal of Mauna Kea Technologies is to use state-of-the-art technology to improve the diagnosis and treatment of patients in medicine. The business model of Mauna Kea Technologies is based on the development and sale of products used in the diagnosis and treatment of patients. Mauna Kea Technologies' products are based on confocal microscopy, a technology that allows for significant magnification and examination of tissue and cell structures. The technology is used in various areas of medicine, such as gastroenterology, hepatology, pulmonology, and oncology. Mauna Kea Technologies is divided into different divisions to meet the requirements of different areas of medicine. The first division is Cellvizio, a confocal microscope used in endoscopy. Cellvizio allows doctors to see real-time images, enabling quick and accurate diagnosis. The second division is Lumicell, used in surgery. Lumicell allows surgeons to detect and remove cancer cells in real time, enabling a more precise operation. The third division is Orally, a device used in dentistry. Orally is a mobile confocal microscope that allows dentists to detect microorganisms in real time and obtain a more accurate picture of their patients' oral health. The fourth division is Pediatric, a confocal microscope specifically designed for pediatrics. It allows doctors to see images that are 10 times larger than traditional medical devices. Mauna Kea Technologies is a leading provider of medical devices based on confocal microscopy. The company has already partnered with some of the leading medical institutions worldwide to promote the use of its products in the diagnosis and treatment of patients. Mauna Kea Technologies has also received awards for its products and excellent research and development, including the CES Innovation Award, the World Economic Forum Technology Pioneer Award, and the Galien Medical Award. Mauna Kea Technologies' products have the potential to revolutionize the way diseases are diagnosed and treated. Confocal microscopy allows doctors to obtain high-resolution images and detect diseases at a much earlier stage than traditional medical devices. With its products, the company has already saved countless lives and contributed to improving the quality of medical care. In summary, Mauna Kea Technologies is an innovative and leading company in the medical technology industry. With its state-of-the-art products and the use of confocal microscopy, the company has revolutionized the way diseases are diagnosed and treated. Mauna Kea Technologies will continue to be a key player in the medical technology industry in the future and will undoubtedly continue to contribute to improving global healthcare. Mauna Kea Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mauna Kea Technologies stock

FCF Conversion Rate (FCF/EBITDA) of Mauna Kea Technologies is -36.65 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Mauna Kea Technologies changed from 62.85 % to -36.65 %, representing a -158.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Mauna Kea Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Mauna Kea Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Mauna Kea Technologies

All Key Metrics — Mauna Kea Technologies